Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 20, 2026 08:59 ET | Source: Applied Biologics

Applied Biologics Announces Submission of XWRAP® Translational Research Abstract for Consideration at SAWC Fall 2026

Applied Biologics announces submission of XWRAP® translational research abstract to SAWC Fall 2026.
July 09, 2026 09:02 ET | Source: Applied Biologics

Applied Biologics Introduces ECM Preservation Technology™ as the Proprietary Manufacturing Platform Behind XWRAP®

Applied Biologics introduces ECM Preservation Technology™ (EPT™), the proprietary manufacturing platform behind XWRAP®.
July 07, 2026 10:35 ET | Source: Applied Biologics

Applied Biologics Announces VA Federal Supply Schedule Contract Modification Supporting Long-Term Access to XWRAP®

Applied Biologics' VA FSS contract shifts to Evergreen structure, enabling potential XWRAP® access for up to 20 years.
July 01, 2026 11:45 ET | Source: Applied Biologics

Applied Biologics Announces Expanded Strategic Focus on Surgical Applications of XWRAP®

Applied Biologics expands strategic focus to surgical applications of XWRAP® across multiple specialties.
June 30, 2026 10:29 ET | Source: Applied Biologics

Applied Biologics Announces National Commercial Expansion to Support Continued Growth of XWRAP® and Future Biologic Product Pipeline

Applied Biologics expands its national commercial organization to support XWRAP® growth and future pipeline commercialization.
June 17, 2026 11:38 ET | Source: Applied Biologics

Applied Biologics Announces Completion of Planned Enrollment Activities in the CAMPX Randomized Controlled Trial Evaluating XWRAP®

Applied Biologics completes enrollment in the CAMPX RCT evaluating XWRAP® for chronic diabetic foot ulcers across 23 SerenaGroup sites.
June 09, 2026 14:31 ET | Source: Applied Biologics

Applied Biologics Receives FDA Clearance to Advance BIOxHEAL Into Phase 3 Clinical Development for Diabetic Foot Ulcers

Applied Biologics receives FDA IND clearance for BIOxHEAL, advancing its lead biologic therapy into Phase 3 clinical trials for diabetic foot ulcers.
June 09, 2026 07:23 ET | Source: SNS Insider pvt ltd

Tissue Engineered Skin Substitutes Market to Value USD 3.07 Billion by 2035, Growing at a 6.91% CAGR – SNS Insider

Austin, United States, June 09, 2026 (GLOBE NEWSWIRE) -- “According to SNS Insider, the Tissue Engineered Skin Substitutes Market was valued at USD 1.59 billion in 2025 and is projected to reach USD...
June 03, 2026 07:00 ET | Source: SNS Insider pvt ltd

Wound Irrigation Systems Market to Skyrocket USD 430.05 Million by 2035 as Chronic Wound Cases and Surgical Volumes Rise Worldwide | SNS Insider

Austin, June 03, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Wound Irrigation Systems Market was valued at USD 307.87 Million in 2025 and is expected to reach USD 430.05 Million by 2035,...
May 01, 2026 06:00 ET | Source: SNS Insider pvt ltd

Wound Cleanser Products Market Size is Projected to be USD 5.17 Billion by 2035; Industry is Propelling Owing to the Growing Technological Investments Globally

Wound Cleanser Products Market By Product Type, Formulation Type, By Application, By End-User and By Region | Global Forecast 2025–2035